Cellectar Biosciences, Inc. (CLRB) income statement
CLRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.89−0.04 (-3.81%)
Close on Nov 18, 2026Market cap $8.37MP/E –Yield –
Cellectar Biosciences, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -190.9%
Financial strength
- Current ratio
- 6.66
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 649.0%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.28
- Dividend yield
- –
See a number that looks wrong?